2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings Of The National Academy Of Sciences Of The United States Of America 2015, 112: 14325-14330. PMID: 26578779, PMCID: PMC4655544, DOI: 10.1073/pnas.1518808112.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancer patientsMicrovascular densityInterstitial fluid pressureNeoadjuvant bevacizumabBevacizumab monotherapyPathologic responseCancer patientsImproved pathologic responsePhase II studyPotential predictive biomarkersHER2-negative BCBasal-like subtypePreoperative bevacizumabPaclitaxel chemotherapyII studyComplete responseCombination therapyPredictive biomarkersPlasma biomarkersVascular normalizationBevacizumabVascular densityNew therapiesTissue biopsies
2012
A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).
Tolaney S, Duda D, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio J, Ligibel J, Isakoff S, Fukumura D, Winer E, Krop I, Jain R. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 1026-1026. DOI: 10.1200/jco.2012.30.15_suppl.1026.Peer-Reviewed Original ResearchTN breast cancerBreast cancerInterstitial fluid pressureMiller-PayneTN tumorsHER2-negative operable breast cancerMean interstitial fluid pressureHormone receptorsMP responseAddition of BevAxillary LN involvementDose-dense doxorubicinTriple-negative cohortOperable breast cancerPhase II studyPredictors of responseMean vascular densityPreoperative bevacizumabLN involvementII studyOverall cohortPathologic responseBiomarker predictorsNegative cohortPharmacodynamic effects